Bristol-Myers Squibb’s tax policy sits at the intersection of several recent legal changes that have pushed the company’s GAAP effective tax rate to 24.4% for fiscal year 2025, above the 21% federal statutory rate.1U.S. Securities and Exchange Commission. Bristol-Myers Squibb Company Press Release The Inflation Reduction Act added three new taxes touching the company: a 15% corporate alternative minimum tax, a 1% excise tax on stock buybacks, and an escalating excise tax for manufacturers that refuse to negotiate drug prices with Medicare. A 2025 federal law reversed the requirement to capitalize domestic research spending. And the OECD’s global minimum tax is reshaping how profits earned outside the United States are taxed. Each of these changes has a distinct effect on how BMS structures its operations and reports results.
How BMS Governs Its Tax Function
Bristol-Myers Squibb publishes a Global Tax Policy committing the company to paying all required taxes in every country where it operates, including income taxes, property taxes, customs duties, employment taxes, excise taxes, and value-added taxes.2Bristol-Myers Squibb. Global Tax Policy and Approach The company also claims available deductions, credits, and incentives to the extent the law allows.
The tax function reports to the Chief Financial Officer. Tax risks are periodically discussed with the Audit Committee of the Board of Directors, and decisions carrying significant weight go to the full Board. The company maintains a transfer pricing policy aligned with OECD guidelines, which matters for a pharmaceutical business whose profits often trace back to intellectual property that can be held in different jurisdictions. The policy calls for cooperative engagement with tax authorities and for resolving disputes through documentation and dispute-resolution channels before escalation.2Bristol-Myers Squibb. Global Tax Policy and Approach
The Three Inflation Reduction Act Taxes That Hit BMS
Corporate Alternative Minimum Tax
The Inflation Reduction Act of 2022 created a 15% minimum tax on the adjusted financial statement income of large corporations, effective for tax years beginning after December 31, 2022.3Internal Revenue Service. Corporate Alternative Minimum Tax It applies to companies with average annual financial statement income above $1 billion, a threshold Bristol-Myers Squibb clears easily.4Internal Revenue Service. IRS Clarifies Rules for Corporate Alternative Minimum Tax
The mechanic is a floor. The company calculates its regular corporate income tax, then separately calculates 15% of adjusted financial statement income (net of foreign tax credits). If the second number is higher, the company owes the difference.5Office of the Law Revision Counsel. 26 USC 55 – Alternative Minimum Tax Imposed For a pharma company, traditional deductions for research and other incentives can no longer push the effective federal rate below 15% of book income. Finance teams now run parallel calculations tracking both regular tax liability and any potential CAMT obligation.
Drug Price Negotiation Excise Tax
Under Section 5000D, if a manufacturer of a designated drug fails to reach a negotiated price agreement with Medicare, an excise tax applies to every sale of that drug. The applicable percentage climbs the longer the manufacturer holds out: 65% for the first 90 days, 75% from day 91 through 180, 85% from day 181 through 270, and 95% thereafter.6Internal Revenue Service. Notice 2023-52
Those percentages are not conventional rates. The percentage represents the ratio of the excise tax to the sum of the tax plus the sale price, so at 95% the excise tax on a single sale is roughly 19 times the sale price itself. The structure is designed to make refusal to negotiate economically irrational.7Federal Register. Excise Tax on Designated Drugs For Bristol-Myers Squibb, which markets several high-revenue drugs eligible for selection, the practical effect is a strong incentive to participate in the program regardless of the company’s views on pricing policy.
Stock Buyback Excise Tax
The Act also introduced a 1% excise tax on stock repurchases by publicly traded domestic corporations.8Office of the Law Revision Counsel. 26 USC 4501 – Repurchase of Corporate Stock The tax applies to the fair market value of shares bought back during the tax year, reduced by the value of new stock issued in the same period.9U.S. Department of the Treasury. Treasury and IRS Release Proposed Regulations on Stock Repurchase Excise Tax A “covered corporation” includes any domestic company whose stock trades on an established securities market, so BMS qualifies.
At 1%, the levy is modest compared with the other IRA provisions, but it changes the math when the company chooses between dividends and buybacks. For a company that repurchases billions of dollars in stock annually, even a 1% charge produces a meaningful line item.
Research and Development Tax Treatment
R&D tax treatment has whipsawed pharmaceutical companies in recent years. The Tax Cuts and Jobs Act of 2017 required companies to capitalize and amortize research spending starting in 2022, with domestic expenses spread over five years and foreign research over fifteen. The rule was widely unpopular in the industry because it pushed up near-term taxable income even as drug-development spending kept rising.
In 2025, Congress reversed course for domestic spending. Public Law 119-21 carved domestic research expenses out of Section 174 and created a new Section 174A, restoring the ability to deduct domestic research costs in the year they are incurred.10Internal Revenue Service. Revenue Procedure 2025-28 Companies can elect to amortize domestic expenses over a period of at least 60 months instead, but the immediate deduction is the default. Foreign research expenses remain subject to 15-year amortization under the amended Section 174.11Office of the Law Revision Counsel. 26 USC 174 – Amortization of Research and Experimental Expenditures
This split treatment matters because BMS conducts research on both sides of the border. Clinical trials, laboratory work, and drug development performed in the United States now get favorable treatment again, while the same work done abroad must be capitalized and recovered slowly. The distinction is a real incentive to keep research on U.S. soil.
Research Credit and Orphan Drug Credit
Separately from the deduction rules, Section 41 provides a credit equal to 20% of qualified research expenses above a base amount calculated from historical spending.12Office of the Law Revision Counsel. 26 USC 41 – Credit for Increasing Research Activities Qualifying activities must meet a four-part test that includes eligibility under Section 174, a technological nature grounded in the physical or biological sciences, an aim to develop a new or improved business component, and a process of experimentation.13Internal Revenue Service. Audit Techniques Guide – Credit for Increasing Research Activities Most pharmaceutical R&D clears those tests; the practical challenge is documentation of labor, supplies, and contract research costs tied to qualifying projects.
The orphan drug tax credit under Section 45C provides a credit equal to 25% of qualified clinical testing expenses for drugs targeting rare diseases or conditions.14Office of the Law Revision Counsel. 26 USC 45C – Clinical Testing Expenses for Certain Drugs for Rare Diseases or Conditions Qualifying costs cover human clinical testing after FDA orphan designation and before approval. Testing funded by a grant or government contract does not qualify, and expenses used for the orphan credit generally cannot also count toward the Section 41 credit. The rate was 50% originally and was cut to 25% by the Tax Cuts and Jobs Act. Testing conducted outside the United States qualifies only if there are insufficient test subjects domestically.
Global Minimum Tax Under Pillar Two
The OECD/G20 Inclusive Framework’s Global Anti-Base Erosion rules, known as Pillar Two, are the most significant international tax change facing BMS. They ensure that large multinational groups pay at least a minimum level of tax on income earned in each jurisdiction where they operate.15OECD. Global Anti-Base Erosion Model Rules (Pillar Two) Where the effective rate in a country falls below 15%, a top-up tax brings the total rate on excess profits up to that floor.16OECD. Global Minimum Tax
The rules generally apply to multinational groups with consolidated annual revenue of at least €750 million. BMS operates in dozens of countries, so implementation requires a jurisdiction-by-jurisdiction calculation of income and taxes. A substance-based income exclusion tied to payroll costs and tangible asset values partially shields income linked to real employees and physical facilities. Income from intangibles, including patents on major drugs, is exactly what the rules aim to capture. Parking intellectual property in a low-tax jurisdiction to reduce a global tax bill is far less effective under Pillar Two than it was.
Adoption has been staggered. Many EU member states and other major economies enacted legislation effective from 2024 or 2025; others have announced later dates. BMS therefore has to monitor legislative developments in every country of operation and model the tax consequences of each adoption.15OECD. Global Anti-Base Erosion Model Rules (Pillar Two)
A backstop called the Under-Taxed Profits Rule adds a further wrinkle. If a company’s home country does not collect the top-up tax, other countries where the group operates can step in and collect it, allocated by local payroll and tangible assets. The United States has not enacted Pillar Two legislation, which means BMS could face UTPR charges collected by foreign jurisdictions on U.S.-sourced income that falls below the 15% floor. The issue is politically contentious and the subject of ongoing international negotiation.
EU Public Country-by-Country Reporting
Starting in 2026, the European Union requires large multinationals with global revenue above €750 million to publicly disclose tax information on a country-by-country basis.17European Commission. Public Country-by-Country Reporting The rule applies to non-EU headquartered groups like BMS where the EU presence includes medium-sized or large subsidiaries.
Required disclosures include revenue, profits, taxes paid, number of employees, nature of activities, and retained earnings for each EU member state and each jurisdiction on the EU’s list of non-cooperative tax jurisdictions. Reports must use a standardized electronic format. BMS already files private country-by-country reports with tax authorities under OECD rules, but the EU requirement makes a version of that data publicly accessible for the first time. Investors, journalists, and advocacy groups will be able to see where the company books income and how much tax it pays in each country.17European Commission. Public Country-by-Country Reporting
What the Effective Rate Looks Like Now
For fiscal year 2025, Bristol-Myers Squibb reported a GAAP effective tax rate of 24.4% and a non-GAAP rate of 18.8%.1U.S. Securities and Exchange Commission. Bristol-Myers Squibb Company Press Release The gap between the 21% statutory federal rate and the 24.4% GAAP figure reflects the layering of state taxes, foreign taxes in higher-rate jurisdictions, and minimum tax obligations on top of the base federal rate. The lower non-GAAP figure strips out certain one-time items to show the ongoing tax burden.
These numbers will move. The restoration of immediate deductibility for domestic R&D should reduce taxable income in the near term. The global minimum tax will push up effective rates in jurisdictions where BMS previously paid below 15%. And the drug price negotiation program creates a binary outcome for affected products: either the company negotiates and accepts lower revenue, or it faces an excise tax that dwarfs the revenue itself. Continued volatility in the tax line should be expected as these overlapping regimes settle into steady-state operation.